Global Cardiac Biomarkers Market Research Report-Forecast till 2027

Global Cardiac Biomarkers Market Research Report-Forecast till 2027

$4450 – $6250

The global cardiac biomarkers market is expected to exhibit the highest CAGR of 16.36% during the review period of 2020 to 2027 owing to the largest value of USD 4236.02 Million in 2019.

SKU: MRFR210179 Category: Tags: , , , , ,

Description

Global Cardiac Biomarkers Market Research Report—Forecast till 2027

Market Dynamics
The global cardiac biomarkers market is expected to exhibit the highest CAGR of 16.36% during the review period of 2020 to 2027 owing to the largest value of USD 4236.02 Million in 2019. The overall cardiac biomarkers market is moderately isolated with rising competition, thing dispatches, rising aggregate affiliations, and other key decisions that are embraced to achieve useful usefulness. The vendors battle reliant upon cost, quality, optimal availability, and constancy of things promoted. The advancement of key market players is dependent upon financial circumstances, government support, and industry improvement. For example, COVID-19 has accepted a critical part in the addition of pursued cardiac biomarkers.
The cardiac biomarkers are primarily used as a coordinated demonstrative methodology for different cardiovascular illnesses. The key factors that drive the cardiac biomarkers market are the expanding commonness of cardiovascular illnesses and way of life infections, expanding pervasiveness of cardiovascular sicknesses and way of life illnesses, expansion sought after for sickness explicit therapy and exploration in which cardiac biomarkers are utilized, innovative headways in cardiac biomarkers, and great government drives to make mindfulness identified with cardiovascular sicknesses. Nonetheless, an absence of mindfulness among individuals is relied upon to hamper market development.
Segmental Overview
The global Cardiac biomarkers market has been classified into Type, application, and location of testing.
By Type segment the market has been classified into cardiac biomarker type – Creatine Kinase (CK-MB), Troponins T and I, myoglobin, BNPs, IMA, and others. By Application segment, the market is divided into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. In terms of the location of the testing, the segment is segmented as point-of-care testing and laboratory testing.
Regional Analysis
Geographically, the global cardiac biomarker market has been classified into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
Americas is likely to dominate the global cardiac biomarker market owing to the increasing demand for cardiac testing, increasing prevalence of CVD rate, and the increasing awareness of cardiac diagnostics solutions. The regional market growth is attributed to the high rate of cardiovascular diseases & diabetes, product launch, and acquisition in this region.
The market in Asia-Pacific is rising at the fastest CAGR owing to modernization, increasing disposable incomes, and rising affordability for advanced cardiac treatments. The regional market growth is driven by the rising prevalence of cardiovascular diseases, COPD, and diabetes.
Major Players
The key market players in the global cardiac biomarkers market include Novartis AG (Switzerland), Quidel Corporation (US), Trivitron Healthcare (India), F. Hoffman La Roche Ltd (Switzerland), Johnson & Johnson Services Inc. (US), Abbott Laboratories (US), Siemens (Germany), Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories, Inc (US), Danaher Corporation (US), ACS Biomarker B.V (Netherlands), Randox Laboratories Ltd (UK), and Biomérieux SA (France).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY 14 2 MARKET INTRODUCTION 15 2.1 SCOPE OF THE STUDY 15 2.2 RESEARCH OBJECTIVE 15 2.3 MARKET STRUCTURE 15 2.4 ASSUMPTIONS & LIMITATIONS 16 3 RESEARCH METHODOLOGY 17 3.1 DATA MINING 17 3.2 SECONDARY RESEARCH 18 3.3 PRIMARY RESEARCH 19 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20 3.5 FORECASTING TECHNIQUES 20 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21 3.6.1 BOTTOM-UP APPROACH 22 3.6.2 TOP-DOWN APPROACH 22 3.7 DATA TRIANGULATION 23 3.8 VALIDATION 23 4 MARKET DYNAMICS 24 4.1 OVERVIEW 24 4.2 DRIVERS 24 4.2.1 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASE AND LIFESTYLE RELATED DISEASES 24 4.2.2 INCREASE IN DEMAND FOR DISEASE-SPECIFIC TREATMENT & RESEARCH IN WHICH CARDIAC BIOMARKERS ARE USED 25 4.3 RESTRAINTS 26 4.3.1 LACK OF AWARENESS AMONG PEOPLE 26 5 MARKET FACTOR ANALYSIS 27 5.1 VALUE CHAIN ANALYSIS 27 5.1.1 R&D AND DESIGNING 28 5.1.2 MANUFACTURING 28 5.1.3 DISTRIBUTION & SALES 28 5.1.4 POST-SALES MONITORING 28 5.2 PORTER’S FIVE FORCES MODEL 29 5.2.1 BARGAINING POWER OF SUPPLIERS 30 5.2.2 BARGAINING POWER OF BUYERS 30 5.2.3 THREAT OF NEW ENTRANTS 30 5.2.4 THREAT OF SUBSTITUTES 30 5.2.5 INTENSITY OF RIVALRY 30 5.3 COVID-19 IMPACT ANALYSIS 31 6 GLOBAL CARDIAC BIOMARKERS MARKET, BY TYPE 32 6.1 OVERVIEW 32 6.2 TROPONINS (T AND I) 33 6.3 MYOCARDIAL MUSCLE CREATINE KINASE (CK-MB) 34 6.4 MYOGLOBIN 34 6.5 BRAIN NATRIURETIC PEPTIDE (BNPS) OR NT-PROBNP 35 6.6 ISCHEMIA MODIFIED ALBUMIN (IMA) 35 6.7 ALT/AST 36 6.8 OTHERS 36 7 GLOBAL CARDIAC BIOMARKERS MARKET, BY APPLICATION 37 7.1 OVERVIEW 37 7.2 MYOCARDIAL INFARCTION 38 7.3 CONGESTIVE HEART FAILURE 39 7.4 ACUTE CORONARY SYNDROME 39 7.5 ATHEROSCLEROSIS 40 7.6 OTHERS 40 8 GLOBAL CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING 41 8.1 OVERVIEW 41 8.2 POINT OF CARE TESTING 42 8.3 LABORATORY TESTING 42 9 GLOBAL CARDIAC BIOMARKERS MARKET, BY REGION 43 9.1 OVERVIEW 43 9.2 AMERICAS 45 9.2.1 NORTH AMERICA 47 9.2.1.1 US 49 9.2.1.2 CANADA 51 9.2.2 LATIN AMERICA 52 9.3 EUROPE 53 9.3.1 WESTERN EUROPE 55 9.3.1.1 GERMANY 57 9.3.1.2 UK 58 9.3.1.3 FRANCE 59 9.3.1.4 ITALY 60 9.3.1.5 SPAIN 61 9.3.1.6 REST OF WESTERN EUROPE 62 9.3.2 EASTERN EUROPE 63 9.4 ASIA-PACIFIC 64 9.4.1 CHINA 66 9.4.2 INDIA 67 9.4.3 JAPAN 68 9.4.4 SOUTH KOREA 69 9.4.5 AUSTRALIA 70 9.4.6 REST OF ASIA-PACIFIC 71 9.5 MIDDLE EAST & AFRICA 72 9.5.1 MIDDLE EAST 74 9.5.2 AFRICA 75 10 COMPETITIVE LANDSCAPE 76 10.1 OVERVIEW 76 10.2 MAJOR PLAYERS IN THE GLOBAL CARDIAC BIOMARKERS MARKET 77 11 COMPANY PROFILES 78 11.1 NOVARTIS AG 78 11.1.1 COMPANY OVERVIEW 78 11.1.2 FINANCIAL OVERVIEW 79 11.1.3 PRODUCTS/SERVICES OFFERED 79 11.1.4 KEY DEVELOPMENTS 80 11.1.5 SWOT ANALYSIS 80 11.1.6 KEY STRATEGIES 80 11.2 QUIDEL CORPORATION 81 11.2.1 COMPANY OVERVIEW 81 11.2.2 FINANCIAL OVERVIEW 82 11.2.3 PRODUCTS/SERVICES OFFERED 82 11.2.4 KEY DEVELOPMENTS 82 11.2.5 SWOT ANALYSIS 83 11.2.6 KEY STRATEGIES 83 11.3 ACS BIOMARKER B.V. 84 11.3.1 COMPANY OVERVIEW 84 11.3.2 FINANCIAL OVERVIEW 84 11.3.3 PRODUCTS/SERVICES OFFERED 84 11.3.4 KEY DEVELOPMENTS 84 11.3.5 SWOT ANALYSIS 85 11.3.6 KEY STRATEGIES 85 11.4 RANDOX LABORATORIES LTD 86 11.4.1 COMPANY OVERVIEW 86 11.4.2 FINANCIAL OVERVIEW 86 11.4.3 PRODUCTS/SERVICES OFFERED 86 11.4.4 KEY DEVELOPMENTS 86 11.4.5 SWOT ANALYSIS 87 11.4.6 KEY STRATEGIES 87 11.5 TRIVITRON HEALTHCARE 88 11.5.1 COMPANY OVERVIEW 88 11.5.2 FINANCIAL OVERVIEW 88 11.5.3 PRODUCTS/SERVICES OFFERED 88 11.5.4 KEY DEVELOPMENTS 88 11.5.5 SWOT ANALYSIS 89 11.5.6 KEY STRATEGIES 89 11.6 F. HOFFMAN LA ROCHE LTD 90 11.6.1 COMPANY OVERVIEW 90 11.6.2 FINANCIAL OVERVIEW 91 11.6.3 PRODUCTS/SERVICES OFFERED 92 11.6.4 KEY DEVELOPMENTS 92 11.6.5 SWOT ANALYSIS 92 11.6.6 KEY STRATEGIES 93 11.7 JOHNSON & JOHNSON SERVICES INC. 94 11.7.1 COMPANY OVERVIEW 94 11.7.2 FINANCIAL OVERVIEW 95 11.7.3 PRODUCTS/SERVICES OFFERED 95 11.7.4 KEY DEVELOPMENTS 96 11.7.5 SWOT ANALYSIS 96 11.7.6 KEY STRATEGIES 96 11.8 ABBOTT LABORATORIES 97 11.8.1 COMPANY OVERVIEW 97 11.8.2 FINANCIAL OVERVIEW 98 11.8.3 PRODUCTS/SERVICES OFFERED 98 11.8.4 KEY DEVELOPMENTS 99 11.8.5 SWOT ANALYSIS 99 11.8.6 KEY STRATEGIES 99 11.9 SIEMENS 100 11.9.1 COMPANY OVERVIEW 100 11.9.2 FINANCIAL OVERVIEW 101 11.9.3 PRODUCTS/SERVICES OFFERED 101 11.9.4 KEY DEVELOPMENTS 102 11.9.5 SWOT ANALYSIS 102 11.9.6 KEY STRATEGIES 102 11.10 THERMO FISHER SCIENTIFIC INC. 103 11.10.1 COMPANY OVERVIEW 103 11.10.2 FINANCIAL OVERVIEW 104 11.10.3 PRODUCTS/SERVICES OFFERED 105 11.10.4 KEY DEVELOPMENTS 105 11.10.5 SWOT ANALYSIS 106 11.10.6 KEY STRATEGIES 106 11.11 BIO-RAD LABORATORIES, INC. 107 11.11.1 COMPANY OVERVIEW 107 11.11.2 FINANCIAL OVERVIEW 108 11.11.3 PRODUCTS/SERVICES OFFERED 108 11.11.4 KEY DEVELOPMENTS 108 11.11.5 SWOT ANALYSIS 109 11.11.6 KEY STRATEGIES 109 11.12 DANAHER CORPORATION 110 11.12.1 COMPANY OVERVIEW 110 11.12.2 FINANCIAL OVERVIEW 111 11.12.3 PRODUCTS/SERVICES OFFERED 111 11.12.4 KEY DEVELOPMENTS 112 11.12.5 SWOT ANALYSIS 112 11.12.6 KEY STRATEGIES 112 11.13 BIOMÉRIEUX SA 113 11.13.1 COMPANY OVERVIEW 113 11.13.2 FINANCIAL OVERVIEW 114 11.13.3 PRODUCTS/SERVICES OFFERED 115 11.13.4 KEY DEVELOPMENTS 115 11.13.5 SWOT ANALYSIS 116 11.13.6 KEY STRATEGIES 116 12 APPENDIX 117 12.1 REFERENCES 117 12.2 RELATED REPORTS 117

Related products